Press Releases
Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of…
Read More Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., Feb. 14, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was featured in an interview with Alpha Wolf Trading. In the discussion,…
Read More
Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Feb. 14, 2025– Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)…
Read More
Excerpt from the Press Release: NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers…
Read More
Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S. Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, announced today that they…
Read More
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) Proof-of-concept clinical data from INLIGHT are expected in 2025 Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd.…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These…
Read More
By identifying biomarkers of brain disorders, Cove Neurosciences is working to speed up the development of new treatments. Excerpt from the Press Release: “We know that every patient is different. No two patients with dementia are the same,” says Toronto neurology resident and entrepreneur Nardin Samuel. And yet, she adds, they may end up with…
Read More
Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability RBI-4000’s potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global public health concern, supports further development Excerpt from the Press Release: SAN DIEGO, Feb. 7, 2025 /PRNewswire/ — Replicate Bioscience, a clinical-stage company pioneering novel self-replicating…
Read More